[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591168":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":16,"locations":22,"responsibleParty":32,"collaborators":34,"id":38,"slug":7,"hasResults":39,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":43,"eligibilityCriteria":44,"healthyVolunteers":39,"sex":45,"minAge":46,"maxAge":7,"enrollmentInfo":47,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":7,"overallStatus":25,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"iOMEDICO AG","INDUSTRY",null,[9,13],{"name":10,"affiliation":11,"role":12},"Konstanze Döhner, Prof. Dr. med.","University Hospital Ulm, Germany","STUDY_CHAIR",{"name":14,"affiliation":15,"role":12},"Steffen Koschmieder, Prof. Dr. med.","University Hospital Aachen, Germany",[17],{"name":5,"role":18,"phone":19,"phoneExt":20,"email":21},"CONTACT","+4976115242","0","info@iomedico.com",[23],{"facility":24,"status":25,"city":26,"state":7,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":7,"geoPoint":7,"contacts":29},"Multiple sites all over Germany","RECRUITING","Multiple Locations","Germany","DE",[30],{"name":5,"role":18,"phone":31,"phoneExt":7,"email":21},"+49 761 152420",{"type":33,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR",[35],{"name":36,"class":37},"German Study Group for Myeloproliferative Neoplasms (GSG-MPN)","UNKNOWN","100591168",false,"NCT06976918","Research Platform Myelofibrosis and Anemia","Clinical Research Platform on Treatment, Quality of Life and Outcome of Patients With Primary and Secondary Myelofibrosis and Anemia Who Are JAK Inhibitor Treatment-naïve or JAK Inhibitor Treatment-experienced (RHODOLITE)","RHODOLITE","Inclusion Criteria:\n\n* Confirmed diagnosis of primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) (Note: diagnosis according to WHO-2017, ICC-2022 or WHO-2022 or IWG-MRT criteria, respectively).\n* Diagnosis of anemia at the time of enrollment as per individual, clinical assessment by the local physician.\n* Start of first or subsequent systemic treatment for MF.\n* Informed consent and registration for the GSG-MPN Bioregistry.\n* Willingness and capability to participate in PRO assessment.\n* Signed and dated informed consent form for RHODOLITE at the latest six weeks after start of the respective systemic MF treatment.\n\nExclusion Criteria:\n\n* No systemic therapy for diagnosed primary or secondary MF.\n* Planned allogenic stem cell transplantation (allo-SCT) or active participation in an interventional clinical trial.","ALL","18 Years",{"count":48,"type":49},200,"ESTIMATED","OBSERVATIONAL","The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study, a tumor research platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease and to collect patient-reported outcomes for patients with primary and secondary myelofibrosis and anemia in Germany.",[53,54,55,56,57,58,59],"Primary Myelofibrosis","Secondary Myelofibrosis","Post-polycythemia Vera Myelofibrosis","Post-essential Thrombocythemia Myelofibrosis","Anemia","Myelofibrosis; Anemia","Myelofibrosis","2026-06-03",{"date":62,"type":63},"2026-06-05","ACTUAL",{"date":65,"type":63},"2026-02-19",{"date":67,"type":49},"2031-09",{"name":5,"class":6},1]